Jaguar Health submits Clinical Trial Applications for plant-based drug crofelemer to Italian, German, and UAE health authorities for Short Bowel Syndrome and Microvillus Inclusion Disease.

Jaguar Health submits Clinical Trial Applications for its plant-based drug, crofelemer, to Italian and German health authorities for treating Short Bowel Syndrome (SBS) in adults and Microvillus Inclusion Disease (MVID) in pediatric patients. Applications for trials are also underway in the United Arab Emirates. Crofelemer has received Orphan Drug Designation from the FDA and EMA for both MVID and SBS.

May 09, 2024
3 Articles